We examined the expression levels of microRNAs (miRNAs (miRs)) in colorectal tumors (63 cancer specimens and 65 adenoma specimens) and paired non-tumorous tissues. Decreased expression of miR-143 and -145 was frequently observed in the adenomas and cancers tested, compared with miR-34a downregulation and miR-21 upregulation. Expression profiles of miR-143 and -145 were not associated with any clinical features. As the downregulation of miR-143 and -145 was observed even in the early phase of adenoma formation, the decreased expression of both miRs would appear to contribute mainly to the initiation step of tumorigenesis, not to the progression stage, and not to clinical prognostic factors. For clinical application, we changed the sequences of the passenger strand in the miR-143 duplex and performed chemical modification at the 3 0 -overhang portion of miR-143, leading to greater activity and stability to nuclease. The cell growth inhibitory effect of the chemically modified synthetic miR-143 in vitro was greater than that of endogenous miR-143. The miR-143 showed a significant tumor-suppressive effect on xenografted tumors of DLD-1 human colorectal cancer cells. These findings suggest that miR-143 and -145 are important oncorelated genes for the initiation step of colorectal tumor development and that the chemically modified synthetic miR-143 may be a hopeful candidate as an RNA medicine for the treatment of colorectal tumors.
Introduction
Recent studies indicate that microRNAs (miRNAs (miRs)) have essential roles in many basic biological processes including development, cell proliferation, differentiation and apoptosis. 1 Findings that miRNAs have a role in human cancer is further supported by the fact that more than 50% of miRNA genes are located at chromosomal regions, such as fragile sites, and in regions of deletion or amplification that are genetically altered in a variety of human cancers, suggesting the possible relevance of miRNAs to human cancers. 2 Accumulating evidence suggests that miRNAs are involved in human carcinogenesis as novel types of tumor suppressors or oncogenes. [3] [4] [5] [6] Many miRNAs target mRNAs involved in processes aberrant in tumorigenesis, such as proliferation, survival, cell death and differentiation. In particular, miR-143 and -145 have been shown to function in tumor suppression, because their reduced expression has been observed in most of the human cancer cell lines tested 7 and particularly so in colon cancers 8 and gastric cancers. 9 The enforced expression of both miR-143 and -145 in lowexpression human colon or gastric cancer cells significantly inhibits their cell growth. 7, 9 One of the target genes of miR-143 was determined to be ERK5, which is related to cell growth. [7] [8] [9] [10] [11] These findings indicate the antioncogenic role of miR-143 and -145 is commonly in gastrointestinal cancers.
On the basis of such findings, the relationship between the expression of miR-143 and -145 and the clinicopathological findings in human colorectal tumors is very important. In contrast, RNA interference has become the method to suppress gene expression in vitro and in vivo by using synthetic small interference RNAs in animals. Recent reports show the potential for use of synthetic small interference RNA as therapeutic agents in cancers. 12 For clinical application, the problem of nuclease-resistance must be solved, and more efficient modification of miRNAs and their drug delivery system must be devised. In this study, we showed that the growth inhibitory effect of miR-143 on human colon cancer DLD-1 cells was enhanced by changing the structure of the passenger strand of the miR-143 duplex and that chemical modification of the 3 0 -overhang portion of miR-143 could cause improved resistance against nuclease attack. Given by intravenous injection, such a chemically modified synthetic miR-143 showed a potent tumor-suppressive effect on xenografted human colon cancer cells. These findings suggest the significance of miR-143 and -145 in colorectal tumors and that these modified miRNAs may have a potential therapeutic capacity for colon cancer.
Materials and methods

Patients and samples
All human samples were obtained from patients who had undergone biopsy for diagnosis or surgery for resection at Fujita Health University Hospital (Toyoake, Aichi, Japan), Osaka Medical College Hospital (Takatsuki, Osaka, Japan), Kyouritsu General Hospital (Nagoya, Aichi, Japan) or Saiseikai Ibaraki hospital (Ibaraki, Osaka, Japan). Informed consent in writing was obtained from each patient. Collection and distribution of the samples were approved by each of the appropriate institutional review boards. Sixty-three patients with previously untreated (or recently diagnosed) colorectal cancer and 65 with adenomas were selected. The cancer study group consisted of 18 women and 45 men with a median age of 69 (range, 38-86); and the adenoma group, of 19 women and 46 men with a median age of 61 (range, 21-80). The distribution according to the other clinical parameters is shown in Tables 1 (cancer) and 2 (adenoma). Under a pathologist's supervision, all tissue sample pairs were collected from surgically or endoscopically resected tissues, with these paired samples being from the primary tumor and its adjacent non-tumor mucosal tissue in the same patient. All samples were immediately stored in liquid nitrogen until RNA extraction could be performed. Samples were homogenized by spertel under sterile conditions before total RNA isolation. Total RNA was isolated from the tissues by use of TRIzol containing phenol/guanidium isothiocyanate and treatment with DNase I. RNA concentration and purity were assessed by ultraviolet spectrophotometry. RNA integrity was checked electrophoretically.
Cell culture and cell viability Human colon cancer cell line DLD-1 was grown in RPMI-1640 medium supplemented with 10% (v/v) heatinactivated fetal bovine serum (Sigma, St Louis, MO) and 2 mM L-glutamine under an atmosphere of 95% air and 5% CO 2 at 37 1C. The number of viable cells was determined by the Trypan blue dye exclusion test.
Transfection of DLD-1 cells with miR-143 and/or -145 DLD-1 cells were seeded in six-well plates at a concentration of 1-1.5 Â 10 5 per well (25-35% confluence) the day before the transfection. The mature types of miR-143 (Applied Biosystems, Foster City, CA) and miR-145 (Applied Biosystems) were used for transfection of the cells, which was achieved by using cationic liposomes, that is, Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA), according to the manufacturer's Lipofection protocol. The transfection efficiency was evaluated by transfection of the cells with a duplex small interference RNAfluorescein isothiocyanate (Dharmacon, Lafayette, CO). The transfection efficiency in DLD-1 cells was more than 80%. Nonspecific control miRNA (NS, 57% GC content; Dharmacon) was used as a control for nonspecific effects. The mature types of miR-143 and -145 used in this study were 5 0 -UGAGAUGAAGCACUGUAGCUCA-3 0 and 5 0 -GUCCAGUUUUCCCAGGAAUCCCUU-3 0 , respectively. The effects manifested by the introduction of the mature types of these miRNAs into the cells were assessed at 48 h after the transfection. Total RNA extraction was performed by the method described under 'Patients and samples'.
Human tumor xenograft model and administration of miR-143/liposome complexes Animal experimental protocols were approved by our institute's committee for ethics in animal experimentation, and animal experiments were conducted in accordance with the guidelines for Animal Experiments of Gifu International Institute of Biotechnology. Human colon cancer DLD-1 cells were inoculated at 2 Â 10 6 cells per 100 ml per site into the backs of 5-week-old athymic nude mice, and the inoculation time was set as day 0. Mice were sorted into eight mice per group. Tumor size was monitored by measuring the length (L) and width (W) with calipers, and volumes were calculated by using the following formula: (L Â W 2 ) Â 0.5. At day 10 after the inoculation, synthetic miR-143 (150 mg) or synthetic miR-145 (150 mg) or control (19-mer oligonucleotide from Renilla Luciferase; 5 0 -GGCCUUUCACUACUCCUCA BP-3 0 ) in 50ml was mixed with cationic liposomes (LipoTrust in vivo, Hokkaido System Science, Sapporo, Japan) and the mixture was injected into the tumors once they had reached almost 300 mm 3 . The evaluation of the tumors was performed at 4 weeks after the treatment by killing the mice. In the case of the administration by intravenous injection (via a tail vein; high dose, 50 mg per mouse; low dose, 25 mg per mouse), we started the administration at day 10 and thereafter performed 4 weekly injections. Two weeks later, we killed the mice and performed the evaluation. The synthetic miR-143s were also encapsulated with the cationic liposomes (LipoTrust). The tissue sections from the tumors and other organs were stained with hematoxylin-eosin for pathological evaluation.
Reverse transcription and real-time PCR
To determine the expression of miRNAs by quantitative reverse transcription PCR, we measured their levels by conducting TaqMan MicroRNA Assays using real-time PCR. 10 The PCR primer pairs for miRs-143, -145, -34a, -7 and 21 were obtained commercially from Applied Biosystems. In brief, complementary DNA was synthesized from total RNA by using the gene-specific primers according to the protocol of TaqMan MicroRNA Assays (Applied Biosystems). Reverse transcriptase reactions contained 25 ng of RNA samples, 50 nM stem and loop RT primer (TaqMan MicroRNA Assays; Applied Biosystems), and reagents from a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). Realtime PCR was performed by using a PCR primer (TaqMan MicroRNA Assays; Applied Biosystems) and reagents of LightCycler TaqMan Master (Roche Diagnostics, Mannheim, Germany) in a LightCycler (Software Version 3.5, Roche). The 20-ml PCR reaction mixture included 4.0 ml RT product, 4 ml reagent of LightCycler TaqMan Master (Roche Diagnostics), and 1 ml PCR primer (TaqMan MicroRNA Assays; Applied Biosystems). These reaction mixtures were incubated at 95 1C for 0 -overhang-modification of miR-143 was performed for RNase tolerance. The modified miR-143s were incubated in 10% fetal calf serum, and the amounts of them were evaluated with time by performing a TaqMan miRNA assay using real-time PCR.
Western blotting
The cells were homogenized in chilled lysis buffer comprising 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% sodium dodecyl sulfate, 150 mM NaCl, 1 mM ethylene-diaminetetraacetic acid and 1% Protease Inhibitor Cocktail (Sigma) and stood for 30 min on ice. After centrifugation at 13 000 r.p.m. for 20 min at 4 1C, the supernatants were collected as protein samples. Protein contents were measured with a DC Protein assay kit (Biorad, Hercules, CA). Ten micrograms of lysate protein for western blotting of ERK5 or b-actin was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 10% polyacrylamide gel and electroblotted onto a polyvinylidene difluoride membrane (Du Pont, Boston, MA). After blockage of nonspecific binding sites for 1 h with 5% nonfat milk in phosphatebuffered saline containing 0.1% Tween 20, the membrane was incubated overnight at 4 1C with anti-human ERK5 antibody (Cell Signaling Tec. Inc., Beverly, MA) and antib-actin antibody (ACTB, Sigma). The membrane was then washed three times with phosphate-buffered saline containing 0.1% Tween 20, incubated further with horseradish peroxidase-conjugated sheep anti-mouse or donkey anti-rabbit immunoglobulin antibody (Amersham Biosciences, Piscataway, NJ) at room temperature, and then washed three times with phosphate-buffered saline containing 0.1% Tween 20. The immunoblots were visualized by use of an enhanced chemiluminescence detection kit (New England Biolabs, Beverly, MA). The intensity of the band was determined by densitometric analysis.
Modification for higher nuclease-resistance property of miRNA-143 Oligonucleotides having modification in their 3 0 -overhang regions were chemically synthesized on a DNA-RNA synthesizer by using the phosphoramidite method. 13, 14 Deprotection of bases and phosphates was performed in concentrated NH 4 OH/EtOH (3:1, v/v) at room temperature for 12 h. The 2 0 -tert-butyldimethylsilyl groups were removed by treatment for 12 h with 1.0 M tetrabutylammonium fluoride in tetrahydrofuran at room temperature. The reaction was quenched with 0.1 M triethylammonium acetate buffer (pH 7.0), and desalting was carried out by passage through a Sep-Pak C18 cartridge. Deprotected oligonucleotides were purified by 20% polyacrylamide gel electrophoresis containing 7 M urea and characterized by using a time-of-flight mass spectrometer (matrix-assisted laser desorption/ionization-time-of-flight/mass spectrometry). Complementary strands were mixed and incubated at 90 1C for 5 min. The mixture was gradually cooled to room temperature for 1 hr or more to allow the duplexes to form.
Purification of Argonaute 2 (Ago2)-binding miRNA by using a high-affinity anti-Ago2 monoclonal antibody DLD-1 cells were seeded in six-well plates at a concentration of 2-3.0 Â 10 5 per well the day before transfection. The mature types of miR-143s were used for the transfection of the cells (60 nM), which was achieved by using cationic liposomes, that is, Lipofectamine RNAi-MAX (Invitrogen) according to the manufacturer's Lipofection protocol. Forty-eight hours after the transfection, the cells were collected, lysed and reacted with antiAgo2 antibody from an Ago2-binding miRNA isolation kit (WAKO, Osaka, Japan). Then, the immunobound RNA was eluted from the anti-human Ago2 antibody beads. The purified RNA was examined for the amount of miR-143 by conducting a TaqMan miRNA assay using real-time PCR. miRNA expression data were normalized to let-7a miRNA according to the manufacturer's suggestions and Ct values of three samples.
Statistics and data analysis
The expression levels were designated 41.5 as upregulation and o0.67 as downregulation, which fold changes were obtained from the results of linear discriminant analysis of miRNA expression patterns from 128 pairs of colon tumors and non-tumorous tissues. The tumor/nontumor ratio of each miRNA expression in the samples was also expressed by use of Box-and-whisker plots. Statistical differences between clinicopathologic parameters and miRNA levels of tumor samples were evaluated by using the Pearson's w 2 test or Fisher's extract test between two groups. A P-value of o0.05 was considered to be significant. All calculations were performed using software JMP (version 5.1, SAS Inc, Cary, NC). Correlation coefficients of expressions among the miRNAs tested were determined (JMP). In transfection experiments, differences were statistically evaluated by one-way analysis of variance followed by Fisher's protected least significant difference. A P-value of o0.05 was considered to be statistically significant.
Results
Relationship between the expression of miR-143 and -145 and clinicopathologic findings The clinicopathologic findings and frequencies of upand downregulation of miRNAs tested in a total of 128 patients with colorectal cancer (63 cases) or adenoma (65 cases) are shown in Tables 1-3 . The expression levels of all analyzed miRNAs significantly differed between the tumor and non-tumor adjacent mucosa. Upregulation of miR-7 (Po0.0001) and miR-21 (P ¼ 0.0289), and downregulation of miR-34a (P ¼ 0.0002) were more significant markers in cancers than in adenomas (Table 3 ). In contrast, the downregulation of miR-143 and -145 was frequently observed in cancers and in the smaller adenomas, which suggests that the decreased expression of miR-143 and -145 was closely associated with the initiation of tumor development. The tumor/non-tumor ratio of each miRNA expression in the samples was also expressed as Box-and-whisker plots (Figure 1a) . No association was found between clinical features and the expression of any analyzed miRNAs tested except for the frequent downregulation of miR-143 and -145 in the distal colon. In addition, we found no correlation between the expression of the miRNAs and serum levels of carcino-embryonic antigen (data not shown). MiR-143 and -145 are localized at chromosome 5q33, and they are only 1.7 kb apart from each other. Recently, we considered that they are transcribed the same as primary miRNA. Statistically, the downregulation of miR-143 and -145 showed a considerably similar pattern in the profiles of cancers and adenomas (correlation coefficient: 0.8690). Thus, the discriminate good markers between cancer and adenoma were miR-7, -21 and -34a, whereas the downregulation of miR-143 and -145 was an overall marker of colon tumors (Figure 1a) .
Additive effect of the combined transfection with miR-143 and -145 on growth inhibition On the basis of the results of the expression profiles of miR-143 and -145 in the clinical samples, we examined the effect of the combined enforced expression of miR-143 and -145 on the growth of DLD-1 cells. As shown in Figure 1b , we conducted the combination transfection with miR-143 (20 nM) and miR-145 (20 nM) at a half concentration of the single miR-143 (40 nM) or miR-145 (40 nM), as reported earlier. 9, 15 As the treatment with 20 nM miR-143 or -145 resulted in almost 74 and 78% growth inhibition, respectively compared with that for the control (data not shown), the growth inhibition by this treatment with both miRNAs (20 nM plus 20 nM) showed an additive effect (cancel effect, the viable cell number is MicroRNA-143 and -145 in human colorectal tumors Y Akao et al higher than that of either single treatment; synergistic effect, fewer than that of either single treatment). Under these conditions, the expression levels of miR-143 and -145 were increased by 50-to 500-fold compared with those for the control cells (data not shown). The difference in growth inhibition between each miRNA alone and the combination of miR-143 and -145 was not significant. Furthermore, the combined treatment with miR-143 (40 nM) and miR-145 (40 nM) did not show any increase in the growth inhibition over that obtained with the combination treatment at 20 nM for each (Figure 1b) .
Chemically modified synthetic miR-143 inhibited cell growth in vitro Previously, we found that miR-143 and -145 are downregulated and act as anti-oncomirs in gastrointestinal tumors, [7] [8] [9] which raises the possibility of using agonists of miR-143 and -145 as anti-cancer drugs. For clinical application, we focused on the efficacy of miR-143 and modified the 3 0 -overhang region of double-stranded miR-143 for resistance against nuclease and changed the nucleotide sequence of the passenger strand, which is ordinarily cleaved before assembling the distinct RNAinduced silencing complex (RISC). 8, 16 This procedure resulted in alteration of the entire double-stranded structure in an effort to seek a more potent miR-143 in terms of the growth inhibitory effect. Earlier we found that the addition of an aromatic compound to the 3 0 -overhang region of the RNA-strand enhances the resistance against nuclease. 13 The evaluation of stability of miR-143 was performed by measuring the amount of miRNA by the TaqMan miRNA assay after inoculating each miRNA into 5% fetal calf serum medium (Figure 2a ). Using the 3 0 chemically modified miR-143s available in our laboratory (3 0 -benzen-pyridine (BP); thymidine-thymidine-pyridine), we examined the time course of the amount of miRNAs remaining after adding them to the medium containing 5% fetal calf serum. The miRNA decay was almost complete within 5 min after the addition of the miRNAs in the medium: that is, more than 97% of the miR-143s were degraded by 5 min. Then, the levels of the miR-143 were basically maintained. The addition of BP at the 3 0 -overhang region of miR-143 (miR-143BP) improved the resistance against nuclease, with the amount of miRNA remaining being five-to eightfold more than that obtained with miR-143 from Applied Biosystems (miR-143AB, Figure 2a ). Thymidinethymidine-pyridine also enhanced the stability to a lesser extent.
Second, we changed the passenger's sequences of the mismatch (MM) portions between passenger and guide strands to match (M) ones in miR-143BP/wild (Figure 2b ). Endogenous miR-143 has 4-MM portions (Figure 2b ). We first synthesized two classes of constructs as 3 0 -2 M (miR-143BP/3 0 -2 M) and 5 0 -2 M (miR-143BP/5 0 -2 M), which constructs are shown in Figure 2b . We transfected DLD-1 cells with these synthetic miR-143BPs to examine their potency for growth inhibition. As shown in Figure 2b , the alteration of 2 MMs close to the portion 3 0 to M (miR-143BP/3 0 -2 M) showed a more potent effect on growth inhibition than did that of the others (miR-143BP/5 0 -2 M, miR-143BP/4 M, and wild type). The other miR-143s, which had only 1 MM passenger sequence in each 3 0 or 5 0 2 MM were almost unchanged in terms of growth inhibition compared with 3 0 or 5 0 2 M-alterations of MM (data not shown). We further confirmed that among the various synthetic miR-143BPs the miR-143BP/ 3 0 -2 M was the most potent for the suppression of the protein expression of ERK5, which was previously determined to be one of the major target genes of miR-143 (Figure 2c) . [7] [8] [9] [10] [11] In contrast, the level of ERK5 mRNA was almost unchanged with all the synthesized miR-143s tested by semi-quantitative reverse transcription PCR (data not shown). Thus, such a modification and change in the duplex structure in miR-143 was closely associated with the potency of its growth-suppressive effect on DLD-1 cells. Mature miRNA, having passed through several processing pathways in the cytoplasm and nucleus of the cells, is introduced to the RISC and transferred to target mRNAs to suppress their translation.
8 Argonaute2 (Ago2), one of the main components of RISC, is responsible for mRNA cleavage in the miRNA pathway. [17] [18] [19] In this regard, we estimated the amount of miR-143 included in the RISC after the transfection of DLD-1 cells with Tumor-suppressive effect of chemically modified synthetic miR-143 in vivo To examine the growth-suppressive effect of miR-143 in vivo, we administered miR-143BP/3 0 -2 M by intratumor injection (0.15 mg per mouse) into nude mice bearing DLD-1 tumors ( Figure 3A) . After the inoculation of the DLD-1 cells into the mice (day 0), we injected the modified synthetic miR-143 at day 10, when the tumor volume had reached 300 mm 3 and then evaluated the tumor size at day 38. The growth-suppressing effect of miR-143BP/3 0 -2 M was more potent than that of miR-145BP. Next, we focused on the tumor-suppressive effect of miR-143BP/3 0 -2 M given by intravenous injection (high dose, 50 mg per mouse and low dose, 25 mg per mouse). At day 14, when the tumor volume had reached 300 mm 3 , we sorted the mice into three groups and injected them via a tail vein once weekly for five injections. The tumorsuppressive effect was evaluated by killing the mice and measuring the tumor weight. A significant reduction in tumor weight by miR-143BP/3 0 -2 M in comparison with the tumor weight of the control was observed from 3 weeks after the intravenous injection. At 2 weeks after the last injection (day 56), we evaluated the tumorsuppressive effect of miR-143BP/3 0 -2 M. The tumor/body weight ratio of the miR-143BP/3 0 -2 M-treated mice was dose-dependently decreased compared with that for the control miRNA ( Figure 3B ). Tumor tissues from miR-143BP/3 0 -2 M-treated mice showed disrupted gland-like structures and considerably fewer tumor cells faintly stained with hematoxylin compared with those from the control miRNA-treated mice ( Figure 3C ).
Discussion
Previously, we reported that miR-143 and -145, which are localized at 5q32 and possibly transcribed as the same primary miRNA, 9 were downregulated in six patients with colon cancers; 7 and we found that they function as anti-proliferative miRNAs based on the results of experiments using human colon cancer DLD-1 cells transfected with either miRNA. In this study, the expression levels of miR-143 and -145 in 128 clinical samples of cancers and adenomas were examined by performing TaqMan miRNA assays using real-time PCR. We showed a strongly significant decrease in miR-143 and -145 levels not only in colorectal cancers but also in adenomas, which findings were also made by Michael et al. 20 Interestingly, the reduced expression of both miRNAs was frequently observed in the adenomas smaller than 10 mm in diameter. Therefore, the downregulation of miR-143 and -145 was not associated with clinical prognostic factors such as stage of disease or other clinical features. Collectively, these miRNAs could have potential protective roles against early events of multistep colorectal carcinogenesis. It is very important to determine whether the downregulation of miR-143 and -145 is a genetic event occurring earlier than the genetic alterations of K-ras and APC in adenomas, and this determination is now in progress in our laboratory. Although it has been reported that the expression of miR-21 positively correlates with clinical stage, lymph node positivity and development of distant metastases in patients with colorectal cancer, 21, 22 in our Japanese cases this correlation was not observed. None of the miRNAs tested were correlated with important prognostic factors. However, the upregulation of miR-7 and -21 and downregulation of miR-34a are significant markers in cancers.
ERK5 was already determined to be a target gene of miR-143 by us [7] [8] [9] [10] [11] and Esau et al. MicroRNA-143 and -145 in human colorectal tumors Y Akao et al checkpoint kinase CHEK2 have also been suggested to be candidate target genes of miR-143. As putative targets of miR-145 with potential oncogenic functions are transcription factors such as MYCN, FOS, YES and FLI, cell-cycle promoters such as cyclin D2 and CDK3 and mitogenactivated protein kinase pathway (MAPK) transduction proteins such as MAP3K3 and MAPK4K4 (http:// microrna.sanger.ac.uk/targets/v5). The combined enforced expression of miR-143 and -145 in transfected DLD-1 cells revealed an additive growth inhibitory effect. Thus, the concurrent downregulation of both miRNAs in the initiation step for development of adenoma may be essential. Therefore, miR-143 and -145 could be biomarkers useful for a search for chemopreventive agents for the development of colon cancer.
For clinical application, we changed the 4 MM paired bases between the guide and passenger strands of miR-143 to 2 M of 3 0 2 MM portion (G to C, G to A), resulting in enhanced growth inhibitory activity in human colon cancer DLD-1 cells; and, further, the 3 0 -overhang modification by the addition of BP showed a greater resistance to nuclease among our available modifications, leading to stabilization of miR-143BP in the serum. By using miR-143BP/3 0 -2 M, we obtained similar results with human colon cancer cells SW480 and COLO201.
According to the double-stranded structure of miR-143, the in vitro growth inhibitory activity was considerably reduced in the whole matched alteration, whereas the highest in the 5 0 2-MM miR-143BP duplex; that is, the 5 0 end is less tightly paired to its complement, among the synthesized miR-143s tested. Such an alteration enabled the better efficiency of miR-143BP/3 0 -2 M to enter the RISC ( Figure 2d) ; and, furthermore, the passenger strand may also have been enabled to target genes for cell proliferation and survival, resulting in synergistically increased activity. At least the 5 0 2 MM portions of miR-143BP affected the efficiency to strengthen the miRNA processing pathway, compared with the other altered ones. The 5 0 open structure of the miR-143 duplex seems to contribute to the activity, which is also true in the cases of small interference RNAs. 25 Moreover, it has been shown that the 3 0 -overhang region of a guide strand of miRNA is recognized by the PAZ (Piwi/Argonaute/ Zwille) domain in the Ago2, and the 2-nucleotide MicroRNA-143 and -145 in human colorectal tumors Y Akao et al 3 0 -overhang is accommodated into a binding pocket composed of hydrophobic amino acids in the PAZ domain. [17] [18] [19] Therefore, we consider that BP at the 3 0 -overhang region may be associated with the PAZ domain of Ago2. 13, 14 These findings were reflected by the evidence that the protein level of ERK5, one of the major targets of miR-143, was downregulated in accordance with the activities of the various synthetic miR-143s with modified passenger sequences. Furthermore, the isolation of miRNA by using anti-Ago2 antibody indicated a higher level of miR-143BP/3 0 -2 M in Ago2-binding miRNAs than that of miR-143BP/4 M, which probably caused the more potent suppression of ERK5 expression.
In the athymic nude mouse model, a single intratumoral injection of miR-143BP/3 0 -2 M-induced marked tumor suppression, as shown in in vitro experiments (Figure 2b) . Although it was certain that the tumors actually did not shrink after the intravenous injection of miR-143BP/3 0 -2 M, such a chemically modified synthetic miR-143 showed a potent tumor growth-suppressive effect on xenografted human colon cancer DLD-1 cells in nude mice. Preliminarily, we examined the in vivo distribution of miR-143 in tumor, kidney and liver by performing TaqMan miRNA assays using real-time PCR. There was a significantly increased level of miR-143 in the tumors of animals treated with miR-143 in comparison with that in those given the control miRNA. In addition, the level of miR-143 in the serum was also shown to be increased even at 2 weeks after the last intravenous administration. Thus, the miR-143 and -145 acted as anti-oncomirs, as shown not only by in vitro but also by in vivo experiments. In addition, the chemically modified synthetic miR-143 and -145 would be expected to reach the tumor tissues efficiently, because the levels of miR-143 were increased in the samples from tumors and serum taken at 14 days after the last administration (data not shown). We must further examine the transport systems of miRNAs after the intravenous administration. Thus, the findings in this study suggest the possibility of clinical application of miR-143 and -145 for anticancer agents and the lack of need for drug delivery systems if chemically modified synthetic miRNAs are used. We may consider that concurrent downregulation of miR-143 and -145 possibly leads to the increased potentiality toward colon tumor development. Further study will be needed to disclose the mechanisms involving miR-143 and -145 in the early phase of colon cancer development.
Conflict of interest
The authors declare no conflict of interest.
